Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish
Pharma Has A Moral Obligation To Break Out Of Its Mold
Executive Summary
As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses.